scholarly journals Is monitoring mean platelet volume necessary in breast cancer patients?

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 450-455
Author(s):  
Halil Taskaynatan ◽  
Ahmet Alacacioglu ◽  
Yuksel Kucukzeybek ◽  
Umut Varol ◽  
Yasar Yildiz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Mean Platelet Volume ◽  
Breast Cancer Patients ◽  
Platelet Volume ◽  
Adjuvant Hormone Therapy ◽  
Relationship Of ◽  
The Relationship

AbstractBackgroundMean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy.MethodsData of 261 patients who had pathologically confirmed estrogen or progesterone receptor positive invasive breast cancer and had received hormonotherapy for at least a 5-year period were retrospectively analyzed. MPV levels were measured at baseline and at the first and fifth year of hormone therapy.ResultsAll patients were females and their median age was 50 years (range, 27–78 years). The mean MPV value was significantly increased in all patients in the Tmx, AI, and switch groups over time (p<0.001).ConclusionThis is the first study evaluating the relationship between the 5-year adjuvant endocrine therapy and changes in MPV values in breast cancer patients. Monitoring changes in MPV values may be predictive for severe side effects in breast cancer patients receiving hormone therapy.

The relationship of osteoporosis with severity of pain dirung the treatment of breast cancer patients of childbearing age

2016 ◽  
Vol 21 (3) ◽  
pp. 122-125
Author(s):  
Nataliya. Yu Tretyakova ◽  
E. V Kotljarov
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Comparison Group ◽  
Specific Treatment ◽  
Reproductive Age ◽  
Breast Cancer Patients ◽  
Childbearing Age ◽  
Relationship Of ◽  
The Relationship

Aim. The analysis of the relationship of osteoporosis with severity of pain and the improvement of the diagnosis of osteoporosis in breast cancer (BC) patients of the reproductive age. Methods. There were examined 60 women, including 30 BC patients at the age from 30 to 50 years and 30 women of similar age as comparison group. The examination included a blood test for osteocalcin, calcitonin, alkaline phosphatase, parathyroid hormone, thyroid stimulating hormone, calcium and phosphorus. The degree ofpain in BC patients was evaluated according to the McGill Pain Questionnaire and classification of pain. Osteodensitometry was made in all BC patients and cases from the comparison group. These 30 BC patients were examined prior to the appointment of specific treatment and a half year after the performed treatment Results. In the analysis of 30 breast cancer patients of childbearing age in 26 patients the onset of artificial menopause occurred. Pain syndrome prior to the treatment of the underlying disease was determined in 20% of cases. 6 months after treatment of BC pain breast cancer was detected in 70% of patients. Artificial menopause is associated with the delivery of chemotherapy and shutdown of ovarian function. Hormone therapy with tamoxifen was prescribed to 16 BC patients, 5 of them were transferred to second-line hormone therapy due to side effects of antiestrogens. At that the menopause is the basic condition for the appointment of aromatase inhibitors. In the examination of the whole group ofpatients in 63,3% of cases were revealed to have osteopenia and osteoporosis. Conclusion The prevalence rate of osteoporosis in BC patients of reproductive age is directly related to the performed specific treatment when the appointment of the therapy of osteoporosis it is necessary in complex treatment of cancer patients for the its prevention

The relationship of self-acceptance with decision making duration in cancer patient to perform mastectomy

2021 ◽  
pp. 1-5
Author(s):  
Ayu Ratuati Setiawan ◽  
Feny Tunjungsari ◽  
Mochamad Aleq Sander
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Abnormal Growth ◽  
Self Acceptance ◽  
Observation Method ◽  
Relationship Of ◽  
The Relationship

BACKGROUND: Cancer is a disease caused by abnormal growth of body cells that turn malignant and continue to grow uncontrollably. One of the treatments for breast cancer is mastectomy. The quickness of decision-making determines the survival rate of prognosis patients. OBJECTIVE: This study aimed to determine the relationship of self-acceptance with decision-making duration in cancer patients to perform a mastectomy. METHODS: An analytic observation method with cross-sectional design. The samples were taken by purposive sampling method with 50 samples of breast cancer patients. Data collected include age, last level of education, marital status, profession, stage of cancer during mastectomy, self-acceptance score, and decision-making duration to perform a mastectomy. RESULTS: The data analyzed with the Kruskal–Wallis test. The test showed the relationship of self-acceptance (p = 0.027) with decision-making duration in breast cancer patients to perform a mastectomy. CONCLUSION: In Conclusion, there is a relationship of self-acceptance with decision-making duration in breast cancer patients to perform a mastectomy.

scholarly journals The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients

Surgery Today ◽  
2013 ◽  
Vol 44 (10) ◽  
pp. 1841-1846 ◽  
Author(s):  
Kenji Taketani ◽  
Eriko Tokunaga ◽  
Nami Yamashita ◽  
Kimihiro Tanaka ◽  
Sayuri Akiyoshi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Breast Cancer Patients ◽  
Early Discontinuation ◽  
Adjuvant Hormone Therapy

scholarly journals Psychological Well-Being of Patients with Breast Cancer: A Descriptive Study

Sainteks ◽  
2020 ◽  
Vol 16 (2) ◽  
Author(s):  
S. Widyaningsih ◽  
A. Istifaraswati
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Support Group ◽  
Healthcare Providers ◽  
Well Being ◽  
Breast Cancer Patients ◽  
Psychological Well Being ◽  
Low Levels ◽  
Relationship Of ◽  
The Relationship

The mental impact of cancer on patients is often severe. Patients who have been recently diagnosed with breast cancer tend to experience depression, emotional stress, disappointment, and even despair which later can damage their psychological well-being. This study aims to describe Psychological Well-being among breast cancer patients.134 breast cancer patients were recruited at the Out Patient Department (OPD) of Tugurejo Hospital Semarang city, Indonesia. The data were collected using Ryff Scale Psychological Well-being (RSPWB) questionnaire. Most of the respondents were middle-aged, married, unemployed and had been diagnosed with early stadium of breast cancer. Results showed approximately half of the total respondents (n=64%, 47.8%) experiencing low levels of psychological well-being over the entire period of the sickness. Among four subscales of psychological well-being, “positive relationship with others” subscale was reported to be very low among those respondents. However, almost two thirds of respondents perceived a higher degree of self-acceptance and life purpose while experiencing the illness. Nurses and healthcare providers need to be aware of the importance of counseling service and family/patients support group to improve the relationship of patients with others.Keywords: psychological well-being, breast cancer

scholarly journals 3365 Treatment Interruptions and Early Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients

2019 ◽  
Vol 3 (s1) ◽  
pp. 157-157
Author(s):  
Daqin Mao ◽  
Hong Chang ◽  
Angie Mae Rodday ◽  
Hilal Hachem ◽  
John K. Erban ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Treatment Interruption ◽  
Breast Cancer Patients ◽  
Early Discontinuation ◽  
Adjuvant Hormone Therapy ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

OBJECTIVES/SPECIFIC AIMS: (1) To evaluate the association of patient and clinical factors with adherence to adjuvant hormone therapy (HT). (2) To examine the association of HT-related symptoms and the extent of remediation with early discontinuation of hormone therapy. METHODS/STUDY POPULATION: Retrospective cohort study of risk factors for interruption and early discontinuation of adjuvant hormone therapy in hormone receptor-positive nonmetastatic breast cancer patients diagnosed between 2009 and 2015. This study will include incident hormone receptor-positive breast cancer patients who initiated their HT and were followed at Tufts MC until Dec 31, 2016. Primary data source is electronic medical records (EMRs) RESULTS/ANTICIPATED RESULTS: The primary outcome of this study is early discontinuation to HT, defined as the first treatment gap of greater than or equal to 180 days following the initiation of HT. Treatment interruption, defined as any patient- or provider-initiated treatment gap of ≥ 2 weeks, will be examined as the secondary endpoint. Any HT-related symptoms occurred during a follow-up interval will be captured and categorized into five major types (i.e., vasomotor, neuropsychological, gastrointestinal, gynecological, and musculoskeletal symptoms). Onset and duration of a HT-related symptom will be recorded. Severity of the symptoms will also be rated by clinical oncologists. Remediations in response to HT- related symptoms will be collected and categorized into to two groups (pharmacological or non-pharmacological) and whether they were patient- or provider-initiated. Response to a remediation is defined as complete relief, partial relied, no relief, or with worsening symptoms. Response to a treatment change (i.e., HT switch or hold) was collected separately but using the same criteria. Analyses will be performed on the association between patient and clinical factors with rates of nonadherence (unplanned treatment interruption and/or early discontinuation) of hormone therapy, respectively. We also will explore whether patients with elevated symptoms and/or incomplete remediation will have earlier discontinuation of hormone therapy. DISCUSSION/SIGNIFICANCE OF IMPACT: Through formal chart review, we will establish a dataset that contains highly detailed information about treatment-emergent symptoms and remediations, which will enable us to quantitatively assess the impact of these treatment factors on adherence to hormone therapy for breast cancer. The in-depth analysis of risk factors associated with nonadherence to hormone therapy will inform development of interventions to improve cancer outcomes.

Preoperative mean platelet volume predicts survival in breast cancer patients with type 2 diabetes

Breast Cancer ◽  
2019 ◽  
Vol 26 (6) ◽  
pp. 712-718 ◽  
Author(s):  
Na Li ◽  
Xin-hai Lv ◽  
Xin Wang ◽  
Rui-tao Wang ◽  
Yuan-xi Huang
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Cancer Patients ◽  
Mean Platelet Volume ◽  
Breast Cancer Patients ◽  
Platelet Volume
Sign in / Sign up

Export Citation Format

Share Document